Trial Profile
Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Mirvetuximab soravtansine (Primary) ; Rucaparib (Primary)
- Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Adverse reactions
- 23 Jun 2023 Planned End Date changed from 31 Mar 2023 to 31 Dec 2023.
- 16 Sep 2022 Planned End Date changed from 31 Dec 2022 to 31 Mar 2023.
- 05 Apr 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.